mail
versión imprimible
 
 

3rd TIGIT Axis Therapies

Evvnt Promotion / evvnt
-
07.12.2022 - 08.12.2022  Virtual Event, USA
Time: 8:00 am to 5:00 pm
 
Temas de la conferencia
As immuno-oncology drug development transforms cancer treatment paradigms, preclinical and clinical data continues to demonstrate that the TIGIT axis blockade, particularly in combination with other immune checkpoint inhibitor partners, has strong efficacy. Despite recent clinical setbacks, and with at least 15 anti-TIGIT axis drugs in active clinical development, TIGIT axis targeting remains a promising treatment approach.
La Sociedad Científica
Hanson Wade
Observaciones
Speakers: Murali Ramachandra, Chief Executive Officer, Aurigene Discovery Technologies, David Wald, Associate Professor, Case Western Reserve University, Leonie Meima, Vice President Business Development, Coherus Biosciences
 

Información e inscripción:

https://go.evvnt.com/1234464-2?pid=4832
Ms. Ellie Saunders
 
Categorías
Oncología
Idioma
Inglés
Cuota del Congreso
Conference Only - Industry Pricing - On the Day : USD 2299.00, Conference Only - Academic Pricing - On the Day: USD 2099.00, Conference Only - Service and Solution Provider Pricing - On the Day: USD 2799.00
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."

Österreichisches Rotes KreuzAnästhesie in Entwicklungsländern e. V.Charité International AcademyHelix - Forschung & Beratung WienAMREF - African Medical and Research FoundationÄrzte der WeltHilfswerk AustriaCenter of Excellence